Inventiva SA IVA

European equities traded in the US as American depositary receipts were lower on Tuesday morning, de

Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.

Inventiva SA (IVEVF) reported EUR233.9 million in cash and reaffirmed Q4 2026 top-line NATIV3 data for its MASH therapy lanifibranor, keeping a potential NDA submission on track for H1 2027.

Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026Key highlights from the first half of 2026 and recent Company updatesManagement to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva

Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clin

Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and timing of H1 2026 financial results update Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicin

Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio Carvolix is a listed French commercial- and clinical-stage medical technology companyDeveloping breakthrough AI-driven mini-robots and biomimetic implants to revolutionize interventional cardiology and the treatment of ischaemic stroke Lead technology, TAVIpilot, an FDA-cleared, easy-to-use, AI-driven intraoperative software for TAVI (Transcatheter Aortic Valve Implantation) procedure

Inventiva (ENXTPA:IVA) stock has been relatively flat in the latest session, leaving investors focused on how its clinical stage pipeline in MASH and rare diseases, together with recent share performance, shapes the current risk reward profile. See our latest analysis for Inventiva. Over the past year, Inventiva’s share price return has been mixed, with a 9.1% 1 month gain and a 15.4% decline over 3 months. The 1 year total shareholder return of 34.7% points to earlier buying interest that...

Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “Combined Transaction”) through the issuance of approximately 15.7

European equities traded in the US as American depositary receipts were rising on Thursday morning,

Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Tuesday June 30, 2026, at 2 p.m. at Hôtel Villa M, 24-30 B

Inventiva S.A. (NASDAQ:IVA) is one of the 10 best stocks under $10 offering more than 50% upside. As of the June 24 close, Inventiva S.A. (NASDAQ:IVA) had a strongly bullish consensus sentiment. The stock received Buy ratings from all 9 analysts who provided coverage. Based on a 1-year median price target of $15.75, it currently […]

Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASHClaret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financingLatest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners (‘Claret’), Europe's largest independent growth

Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7 million Underlying Shares) for a repurchase price of €50 million Issued the Tranche A Convertible Bonds (€35 million) and the Tranche B Amortized Bonds (€40 million), for an initial aggregate drawdown of €75 million under the Debt Financing Transaction3 with f

The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.